Melanoma (Skin)
Conditions
Keywords
recurrent melanoma, stage III melanoma, stage IV melanoma
Brief summary
RATIONALE: Vaccines made from a patient's dendritic cells may make the body build an immune response to kill tumor cells. It is not yet known whether combining vaccine therapy with either gp100 antigen or the patient's tumor cells will cause a stronger immune response and kill more tumor cells. PURPOSE: This randomized phase II trial is studying vaccine therapy and gp100 antigen to see how well they work compared to vaccine therapy and patient's tumor cells in treating patients with stage III or stage IV melanoma.
Detailed description
OBJECTIVES: Primary * Compare the tumor-specific immune response, in terms of the number of gp100-specific cytotoxic T-lymphocytes, T-cell production of interferon gamma, or T-cell proliferation in response to in vitro exposure to gp100 and tumor lysate, in patients with stage III or IV melanoma treated with autologous dendritic cells (DC) pulsed with gp100 antigen vs autologous DC fused with autologous tumor cells. Secondary * Compare the safety and toxicity of these regimens in these patients. * Compare the therapeutic effect of these regimens in these patients. OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms. All patients undergo leukapheresis. Peripheral blood mononuclear cells are cultured to generate dendritic cells (DC). * Arm I: Patients undergo surgical harvesting of tumor cells for subsequent fusion. Patients receive vaccination comprising DC fused with autologous tumor cells subcutaneously on day 1. Treatment repeats every 21 days for 3 courses. Patients who achieve a partial (PR) or complete response (CR) may receive an additional 3 courses. * Arm II: Patients receive vaccination comprising DC pulsed with gp100 antigen IV on day 1. Treatment repeats every 21 days for 6 courses. Patients who achieve a PR or CR may receive an additional 6 courses. In both arms, patients are followed monthly for 6 months. PROJECTED ACCRUAL: A total of 40 patients (20 per treatment arm) will be accrued for this study.
Interventions
Given subcutaneously
BIOLOGICALgp100 antigen
Given IV
BIOLOGICALtherapeutic autologous dendritic cells
Given IV
Sponsors
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Study design
Allocation
RANDOMIZED
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed cutaneous melanoma * Stage III or IV disease * Recurrent or de novo stage III disease allowed if disease is unresectable and no definitive treatment is available * gp100- and HLA-A201-positive * Surgically accessible tumor, defined by 1 of the following: * Pulmonary lesions approachable by thoracoscopic procedure * Skin or superficial soft tissue or lymph node lesions amenable to resection under local anesthesia * Malignant ascites or pleural effusion * Measurable disease in addition to surgically accessible tumor \> 2.0 cm * No CNS metastases * No mucosal or ocular melanoma PATIENT CHARACTERISTICS: Age * Any age Performance status * ECOG 0-1 Life expectancy * More than 3 months Hematopoietic * WBC \> 3,000/mm\^3 * Platelet count \> 75,000/mm\^3 Hepatic * Bilirubin \< 2.0 mg/dL Renal * Creatinine \< 2.0 mg/dL Immunologic * No active infection requiring treatment * No clinically significant autoimmune disorder * No immune deficiency disorder * HIV negative Other * Antecubital vein accessible for leukapheresis * No other malignancy within the past 5 years except nonmelanoma skin cancer or squamous cell carcinoma in situ of the cervix * No pre-existing comorbid disease that would preclude study compliance * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective barrier contraception PRIOR CONCURRENT THERAPY: Biologic therapy * No prior melanoma vaccine therapy * More than 6 weeks since prior immunotherapy Chemotherapy * No prior chemotherapy for metastatic melanoma Endocrine therapy * No concurrent corticosteroids Radiotherapy * More than 6 weeks since prior radiotherapy Surgery * Not specified Other * No concurrent systemic immunosuppressive therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immune response | — |
Countries
United States
Outcome results
None listed